Clinical Trial

A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients

Study acronym: ASCERTAIN
Completed
View on ClinicalTrials.gov →
Summary
The aim of this study was to collect existing information from the medical charts of patients enrolled in the ongoing asciminib Managed Access Program (MAP) to better understand the effectiveness and safety of asciminib when used to treat adult patients with Ph+ ALL who are refractory, resistant or intolerant to available treatments.
Trial Details
NCT Number NCT07644351
Lead Sponsor Novartis Pharmaceuticals
Conditions Acute Lymphoblastic Leukemia
Enrollment 37 participants
Start Date 2024-12-16
Primary Completion 2025-09-17 (estimated)
Study Completion 2025-09-17 (estimated)
Updated on ClinicalTrials.gov 2026-06-12